López Sánchez, AliciaPérez Cantero, AlbaTorrado Salmerón, Carlos FélixMartín Vicente, AdelaGarcía Herrero, VíctorGonzález Nicolás González, María ÁngelesLázaro Fernández, AlbertoTejedor Jorge, AlbertoTorrado Durán, SantiagoGarcía Rodríguez, Juan JoséCapilla, JavierTorrado Durán, Susana2024-02-052024-02-052018-06-26López Sánchez, A., Pérez Cantero, A., Torrado Salmerón, C. F. et al. «Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis». Antimicrobial Agents and Chemotherapy, vol. 62, n.o 7, julio de 2018, pp. e00489-18. DOI.org (Crossref), https://doi.org/10.1128/AAC.00489-18.0066-480410.1128/aac.00489-18https://hdl.handle.net/20.500.14352/98759An experimental micellar formulation of 1:1.5 amphotericin B-sodium deoxycholate (AMB:DCH 1:1.5) was obtained and characterized to determine its aggregation state and particle size. The biodistribution, nephrotoxicity, and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial formulation of amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold-higher lung concentrations (18.125 ± 3.985 μg/g after 6 daily doses) and lower kidney exposure (0.391 ± 0.167 μg/g) than liposomal commercial amphotericin B (6.567 ± 1.536 and 5.374 ± 1.157 μg/g in lungs and kidneys, respectively). The different biodistribution of AMB:DCH micelle systems compared to liposomal commercial amphotericin B was attributed to their different morphologies and particle sizes. The efficacy study has shown that both drugs administered at 5 mg/kg produced similar survival percentages and reductions of fungal burden. A slightly lower nephrotoxicity, associated with amphotericin B, was observed with AMB:DCH 1:1.5 than the one induced by the liposomal commercial formulation. However, AMB:DCH 1:1.5 reached higher AMB concentrations in lungs, which could represent a therapeutic advantage over liposomal commercial amphotericin B-based treatment of pulmonary aspergillosis. These results are encouraging to explore the usefulness of AMB:DCH 1:1.5 against this disease.</jats:p>engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal article1098-6596https//doi.org/10.1128/aac.00489-18https://journals.asm.org/doi/10.1128/aac.00489-18open access663/665615.28576.8AspergillosisAphotericin BDeoxycholatePulmonary concentrationsNephrotoxicityEfficacyMicrobiología (Farmacia)Parasitología (Farmacia)Tecnología de los alimentos32 Ciencias Médicas23 Química